Hemispherx Biopharma, Inc. Announces it Has Scheduled Its 2010 Annual Stockholders' Meeting to Occur on March 17, 2011 in Remediation of Notice From the NYSE Amex of Non-Compliance With the Requirement to Hold Its Annual Stockholders' Meeting by the End of 2010
February 23, 2011 13:19 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Feb. 23, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB)announced that notice had been received from the Staff of the NYSE Amex (the "Amex") indicating that the...
Hemispherx Biopharma Appoints Senior Pharma Executive to Key Manufacturing Position
February 17, 2011 10:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Feb. 17, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), announced today the appointment of Mr. Ronald Ritz as Senior Director of...
Hemispherx Biopharma Announces US District Court Grants Final Approval of Settlement of Securities Class Actions
February 17, 2011 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Feb. 17, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") today announced that the United States District Court for the Eastern...
FDA Authorizes Alferon LDO Clinical Study for Treatment and Prevention of Influenza
January 04, 2011 10:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Jan. 4, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced today that the Food and Drug Administration (FDA) has lifted a...
Hemispherx Biopharma, Inc. to Restate 2009 Financial Statements
December 28, 2010 16:56 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Dec. 28, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) announced its intention to restate its financial statements in its Annual Report on Form 10-K for the year...
Hemispherx Biopharma Licenses Alferon N Injection(R) to GP Pharm in Latin America
December 20, 2010 11:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Dec. 20, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced that the Company has entered into an agreement with GP Pharm...
FDA Grants Hemispherx Biopharma Extension in Its Pending NDA for Treatment of Chronic Fatigue Syndrome (CFS)
December 14, 2010 10:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Dec. 14, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced today that the Food and Drug Administration (FDA) granted a 12...
Hemispherx Biopharma Extends GP Pharm License to Mexico for Ampligen to Treat for Chronic Fatigue Syndrome in Latin America
December 09, 2010 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Dec. 9, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced that the Company has amended its June 15, 2010 agreement with GP...
Hemispherx Biopharma Files With the FDA a Request to Maintain as Active Hemispherx NDA for Ampligen(R) to Treat Chronic Fatigue Syndrome (CFS)
November 29, 2010 09:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Nov. 29, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx"), announced that the Company has requested an extension of time in which to...
Hemispherx Publishes New Data on Ampligen(R)'s Activity in Chronic Fatigue Syndrome (CFS)
November 22, 2010 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Nov. 22, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), announced the publication of a peer-reviewed article providing new data on Ampligen®...